Opioid antagonists with minimal sedation for opioid withdrawal

Recent Advances in the Pharmacotherapeutic Management of Drug Dependence and Addiction

“…Seventeen studies assessing the efficacy of acamprosate have been published so far. About 80% of these acamprosate clinical trials across Europe have reported consistent results showing beneficial effects of naltrexone or naloxone [114] (Table 1). Lofexidine is a potent vasodilatory antihypertensive, developed by Nattermann (Sanofi-Aventis).…”

Recent Advances in the Pharmacotherapeutic Management of Drug Dependence and Addiction

“…Seventeen studies assessing the efficacy of acamprosate have been published so far. About 80% of these acamprosate clinical trials across Europe have reported consistent results showing beneficial effects of naltrexone or naloxone [114] (Table 1). Lofexidine is a potent vasodilatory antihypertensive, developed by Nattermann (Sanofi-Aventis).…”

Potential uses of naltrexone in emergency department patients with opioid use disorder

“……”

Transporter-Mediated Disposition of Opioids: Implications for Clinical Drug Interactions

“…Like methadone, buprenorphine has been marketed as an effective maintenance medication for treating opioid addiction (226). Buprenorphine is a semi-synthetic partial μ-opioid receptor agonist and κ-opioid receptor antagonist (227).…”

Recent Advances in the Pharmacotherapeutic Management of Drug Dependence and Addiction

“…Seventeen studies assessing the efficacy of acamprosate have been published so far. About 80% of these acamprosate clinical trials across Europe have reported consistent results showing beneficial effects of naltrexone or naloxone [114] (Table 1). Lofexidine is a potent vasodilatory antihypertensive, developed by Nattermann (Sanofi-Aventis).…”

Potential uses of naltrexone in emergency department patients with opioid use disorder

“……”

Transporter-Mediated Disposition of Opioids: Implications for Clinical Drug Interactions

“…Like methadone, buprenorphine has been marketed as an effective maintenance medication for treating opioid addiction (226). Buprenorphine is a semi-synthetic partial μ-opioid receptor agonist and κ-opioid receptor antagonist (227).…”

Recent Advances in the Pharmacotherapeutic Management of Drug Dependence and Addiction

“…Seventeen studies assessing the efficacy of acamprosate have been published so far. About 80% of these acamprosate clinical trials across Europe have reported consistent results showing beneficial effects of naltrexone or naloxone [114] (Table 1). Lofexidine is a potent vasodilatory antihypertensive, developed by Nattermann (Sanofi-Aventis).…”

Potential uses of naltrexone in emergency department patients with opioid use disorder

“……”

Transporter-Mediated Disposition of Opioids: Implications for Clinical Drug Interactions

“…Like methadone, buprenorphine has been marketed as an effective maintenance medication for treating opioid addiction (226). Buprenorphine is a semi-synthetic partial μ-opioid receptor agonist and κ-opioid receptor antagonist (227).…”